Bremer Andrew A, Arreaza-Rubín Guillermo
1 Pediatric Growth and Nutrition Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
2 Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
J Diabetes Sci Technol. 2019 Mar;13(2):268-270. doi: 10.1177/1932296818823770. Epub 2019 Jan 19.
In an article in Journal of Diabetes Science and Technology, Schliess and coauthors describe the conception and design of the European Automated Glu cose Contro l at H ome for People with Chronic Di sease (CLOSE) initiative for the implementation of artificial pancreas (AP) systems for people with diabetes. The CLOSE consortium aims to develop integrated AP solutions (APplus) tailored to the needs of individuals with type 2 diabetes (T2D) by developing superior risk- and cost-benefit scenarios for AP operation to achieve acceptance by users and caregivers and a high likelihood for reimbursement. CLOSE is integrating the AP platform into the center of a comprehensive product and service package specifically tailored to defined T2D patient groups and care environments, leading to an interactive collaboration with users, health care providers, and other stakeholders in diabetes care. This is a very ambitious but well-conceived and delineated project which takes into consideration most of the relevant factors that may influence AP implementation in T2D care.
在《糖尿病科学与技术杂志》的一篇文章中,施利斯及其合著者描述了欧洲慢性病患者家庭自动血糖控制(CLOSE)倡议的构想和设计,该倡议旨在为糖尿病患者实施人工胰腺(AP)系统。CLOSE联盟旨在通过为AP操作开发卓越的风险和成本效益方案,以实现用户和护理人员的接受以及高报销可能性,从而开发出适合2型糖尿病(T2D)患者需求的集成AP解决方案(APplus)。CLOSE正在将AP平台集成到专门为特定T2D患者群体和护理环境量身定制的全面产品和服务包的中心,从而与糖尿病护理中的用户、医疗保健提供者和其他利益相关者进行互动协作。这是一个非常雄心勃勃但构思巧妙且规划清晰的项目,它考虑到了可能影响T2D护理中AP实施的大多数相关因素。